Drug Discovery World

JUNE 6, 2024

Professor Charles Swanton, Cancer Research UK’s chief clinician, said the melanoma trial results were “extremely impressive”, adding: “The new vaccine approach is another piece of the puzzle that will allow more patients to be cured, hopefully, or fewer patients to suffer disease relapse. months after initial treatment.

Vaccine 147

Vaccine Clinical Trials FDA Approval Research Laboratories 147

The Pharma Data

APRIL 27, 2023

RSV causes over 270,000 hospitalisations and approximately 20,000 in-hospital deaths in adults aged 60 years and older each year in Europe. 1 If approved, GSK’s candidate has the potential to be the first vaccine available to help protect older adults from RSV disease. In the trial, the vaccine candidate showed 82.6% (96.95% CI, 57.9–94.1,

Virus 40

Virus Vaccine Trials Clinical Trials 40

Drug Discovery World

AUGUST 31, 2022

A new study, published in the Annals of Internal Medicine , shows that higher levels of viral antigen in the blood, which could indicate ongoing SARS-CoV-2 replication, correlated with more severe disease. . Analysis of Covid patient blood samples.

Hospitals 130

Hospitals Trials Virus International 130

Drug Discovery World

SEPTEMBER 13, 2023

These results are compared to those of a recent study, which has shown showing that the SARS-CoV-2 virus causing Covid-19 can trigger the activation of the HERV-W retrovirus, which may result in post-infectious syndromes or diseases associated with persistent HERV-W ENV expression in genetically predisposed individuals.

Protein Expression 130

Protein Expression Clinical Trials Hospitals Trials 130

The Pharma Data

DECEMBER 29, 2020

29, 2020 /PRNewswire/ — Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation. As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load and clinical outcomes.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

Codon

AUGUST 26, 2024

When COVID-19 emerged in 2019, by contrast, mRNA vaccines developed by Pfizer and Moderna took just 326 days from the initial sequencing of the virus to gaining approval for emergency use. These drugs would be ideal tools to bridge the wait for a vaccine against a quickly-spreading virus. Unsubscribe any time.

RNA 87

RNA Virus DNA Vaccine 87

The Pharma Data

JUNE 7, 2023

This authorisation for Arexvy means eligible adults can be vaccinated against RSV disease for the first time, reinforcing GSK’s long history of vaccine innovation. 1 Those with underlying medical conditions, such as diabetes and chronic heart and lung disease, drive the majority of RSV hospitalisations.

Virus 40

Virus Vaccine Disease Trials 40

The Pharma Data

APRIL 8, 2022

Using a Human Lung Chip that replicates the structures and functions of the lung air sac, or “alveolus,” the research team discovered that applying mechanical forces that mimic breathing motions suppresses influenza virus replication by activating protective innate immune responses. During his Ph.D.

Virus 52

Virus Immune Response Disease Clinical Trials 52

Drug Discovery World

FEBRUARY 27, 2023

However, the researchers urge caution as the majority of patients have not reached the age of four to five years where the most severe stages of disease progression typically present. Patients with MPS-IIIA have a mutation in the SGSH gene, causing them to lack an enzyme which normally breaks down large sugar molecules.

Therapies 130

Therapies Trials Virus Disease 130

The Pharma Data

SEPTEMBER 14, 2020

A new antibody treatment is to be trialled on Covid-19 patients in UK hospitals. It forms part of the UK Recovery Trial, which found that a cheap steroid called dexamethasone could save lives. We need to know, and the way to know is to do the trials that will tell us whether that hope turns into reality.”.

Trials 52

Trials Immune Response Virus Vaccine 52

PLOS: DNA Science

JULY 27, 2023

That information led, thanks to vaccine shelved from the first SARS circa 2003, to the rapid development and deployment of mRNA vaccines against the new infectious disease. The owners of the felines all reported feeding their pets raw meat, and samples of the meat revealed not only flu virus genetic material, but also infectious virus.

Disease 92

Disease DNA Virus RNA 92

Drug Discovery World

JULY 12, 2022

It outlines that whilst there are 61 vaccine candidates in clinical development targeting diseases listed on WHO’s bacterial priority pathogen list 2 , most of these will not be available anytime soon. . Haemophilus influenzae ?type type b) Tuberculosis? mycobacterium tuberculosis) ?and and Typhoid fever ( Salmonella? Typhi). .

Vaccine 130

Vaccine Hospitals Clinical Trials Disease 130

The Pharma Data

JANUARY 20, 2021

Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease. The DSMC comprises independent experts who will assess the patient safety data, and, if needed, critical efficacy endpoints of the trial.

Hospitals 52

Hospitals Trials International Clinical Trials 52

The Pharma Data

AUGUST 20, 2020

Medical detection dogs Bramble (left) and Lexi during a visit to Kettering General Hospital. NHS staff are taking part in a trial to see if dogs can sniff out Covid-19 – even in people who are asymptomatic. If the trial is successful, the dogs could be used at UK airports to screen people arriving from abroad.

Trials 52

Trials Nurses Hospitals Virus 52

The Pharma Data

MAY 16, 2022

million symptomatic cases of the virus, as well as 690,000 hospitalizations and more than 110,000 deaths. She adds that the results, “highlight the opportunity to continue widespread vaccination uptake to prevent COVID-19 related disease and generate societal benefits.”

Vaccine 52

Vaccine Hospitals Virus Production 52

The Pharma Data

MARCH 8, 2021

The companies today reported findings on one secondary objective from the Phase 2a study, showing a reduction in time (days) to negativity of infectious virus isolation in nasopharyngeal swabs from participants with symptomatic SARS-CoV-2 infection, as determined by isolation in Vero cell line culture. This press release features multimedia.

Trials 69

Trials Virus RNA Research Laboratories 69

Drug Discovery World

FEBRUARY 5, 2024

Williams discussed the advantages of the company’s ‘disease agnostic’ small molecule degraders, and its success so far in translating results from preclinical to clinical tests in dermatology, inflammation and oncology indications. Product launches More than 400 exhibitors are at the event this year, many of whom are launching new products.

Small Molecule 162

Small Molecule Assay Development Production Science 162

The Pharma Data

DECEMBER 23, 2020

23, 2020 — Because COVID-19 is known to raise the odds for dangerous blood clots, blood thinners have quickly become part of routine care for many hospitalized patients. The three trials are being conducted on four continents. WEDNESDAY, Dec. “Such abnormal bleeding could be lethal if not quickly diagnosed and treated.”

Trials 52

Trials Hospitals Clinical Trials Doctors 52

The Pharma Data

OCTOBER 28, 2020

Today’s data, involving an additional 524 patients from the ongoing Phase 2/3 trial, provides definitive final virology results and meets the clinical endpoint of reducing medical visits. In the overall patient group with detectable virus at baseline, the average daily reduction in viral load through day 7 was a 0.36

Virus 40

Virus Trials Clinical Trials Production 40

Drug Discovery World

APRIL 20, 2023

To date, it seems that the likely mechanism of post- Covid-19 cognitive impairment is neuroinflammation triggered by the peripheral / systemic inflammation caused by the virus. Alzheimer’s disease), or by initiating a new one. There is strong evidence for widespread brain changes following Covid-19. depression).

Drug Development 246

Drug Development Clinical Trials Drugs Virus 246

The Pharma Data

JANUARY 17, 2021

The treatment could be administered in primary care centers to people who test positive for COVID-19, avoiding hospitalization due to the progression of the disease and complementing the vaccine in the early phase after vaccination. BARCELONA, Spain , Jan. 18, 2021 /PRNewswire/ — Grifols (MCE: GRF, MCE: GRF.P,

Clinical Trials 52

Clinical Trials Treatment Trials Hospitals 52

Codon

JANUARY 21, 2024

Today, refined versions of these human challenge studies have become standard practice in testing vaccines for vector-borne diseases (e.g., yellow fever, malaria, and dengue), evaluating new drugs or treatments, and studying pathogenesis, the process by which a disease develops. Why are challenge trials becoming more popular?

Vaccine 111

Vaccine Trials Disease Virus 111

The Pharma Data

DECEMBER 3, 2020

New Tau Protein is Abnormal in Very Early Alzheimer’s Disease. Investigators with the University of Gothenburg identified new forms of tau protein that become abnormal in the very early stages of Alzheimer’s disease, even before the development of cognitive problems. Kidney Disease Leading Risk Factor for COVID-related Hospitalization.

Disease 52

Disease Research Virus Hospitals 52

The Pharma Data

DECEMBER 17, 2020

(NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. “The investigational cocktail is now available to indicated high-risk U.S.

Hospitals 52

Hospitals Production Clinical Trials Virus 52

The Pharma Data

SEPTEMBER 25, 2020

A trial of a new vaccine that appears to train the immune system to fight coronavirus has begun in the UK. Early tests showed the jab, developed by US biotechnology company Novavax, leads to high levels of virus-fighting antibodies being produced. The trial on 10,000 people will now see if the vaccine can prevent people getting ill.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

DECEMBER 20, 2020

Followed by Russia , Indonesia, and Korea, the second phase of the COVID-19 clinical trial was approved in Italy on Friday, December 18, 2020. Currently, it is smoothly progressing with the approval for Phase 2 clinical trials in four countries, and it is expected to see the results sequentially starting as early as the third quarter of 2021.

Clinical Trials 40

Clinical Trials Treatment Trials Hospitals 40

The Pharma Data

OCTOBER 30, 2020

30, 2020 /PRNewswire/ — The IDMC also recommends continuation of enrollment in the REGN-COV2 outpatient trial. NASDAQ: REGN) received today a recommendation from the independent data monitoring committee (IDMC) for the REGN-COV2 antibody cocktail treatment trials for COVID-19 that the current hospitalized patient trial be modified.

Hospitals 52

Hospitals Virus Production Clinical Trials 52

The Pharma Data

APRIL 3, 2021

The CoVIg-19 Plasma Alliance today announced that the Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), did not meet its endpoints. About the ITAC Trial.

Clinical Trials 52

Clinical Trials Trials Hospitals Treatment 52

The Pharma Data

DECEMBER 3, 2020

Centers for Disease Control and Prevention warned Wednesday that the coming winter months might be the darkest period yet in the coronavirus pandemic. Another record-breaking day of COVID-19 hospitalizations and deaths underscored Redfield’s grim warning. THURSDAY, Dec. 3, 2020 – The head of the U.S. Things are not shut down.”

Hospitals 52

Hospitals Long-Term Care Facilities Vaccine Nurses 52

The Pharma Data

MARCH 11, 2021

This was measured by improved time to hospital discharge up to day 28 in patients with severe COVID-19 pneumonia receiving standard of care. No new safety signals were identified for Actemra/RoActemra in the REMDACTA trial. The full results of the trial will be submitted for publication in a peer-reviewed journal later this year.

Trials 52

Trials Hospitals Treatment Science 52

The Pharma Data

AUGUST 7, 2020

The governing body claims this proposal could have positive effects on mitigating burdensome requirements for gene therapy clinical trials in the future. In this light, Pharma IQ’s weekly round-up focuses on advancing therapies and clinical trials to combat Covid-19.

Clinical Trials 52

Clinical Trials Trials Packaging Therapies 52

The Pharma Data

JANUARY 21, 2021

Senhwa’s Silmitasertib is an oral medication, targeting the host protein kinase CK2 (casein kinase 2), where virus mutations are unlikely to affect its anti-viral and anti-inflammatory efficacy. It is thought that Silmitasertib challenges the virus’ ability to replicate quickly and spread to nearby healthy cells.

Trials 52

Trials Treatment Small Molecule Hospitals 52

The Pharma Data

MARCH 14, 2023

Based on our clinical trial results, we are hopeful that QDENGA could have a positive impact on the incidence of symptomatic dengue in Brazil, including dengue cases that require hospitalization. The TIDES trial met its primary endpoint of overall vaccine efficacy (VE) by preventing 80.2% 2 In 2022 Brazil saw more than 1.4

Vaccine 40

Vaccine Virus Hospitals Trials 40

Drug Discovery World

NOVEMBER 1, 2022

In September this year, Aucentra Therapeutics announced that it received regulatory approval to progress to a Phase I/II trial for Auceliciclib in combination with Temozolomide for recurrent/refractory Glioblastoma multiforme (GBM) patients 3. . Ground-breaking therapies . Further, the five-year survival rate for glioblastoma is 4.6%

Drugs 130

Drugs Science Therapies Clinical Trials 130

The Pharma Data

MARCH 25, 2021

TAK-003 is Being Studied for the Prevention of Dengue Due to any Dengue Virus Serotype in Individuals Ages Four to 60. Dengue outbreaks, which result in half a million hospitalizations globally each year, can overwhelm communities and governments because of the broad impact on the health care system. About TAK-003.

Vaccine 52

Vaccine Virus Trials Hospitals 52

The Pharma Data

FEBRUARY 23, 2022

* Final analysis of the global VAT02 booster trial confirms universal ability to boost neutralizing antibodies 18- to 30-fold across vaccine platforms (mRNA, adenovirus). * efficacy against any symptomatic COVID-19 disease, in line with expected vaccine effectiveness in today’s environment dominated by variants of concern.

Vaccine 52

Vaccine Virus Trials Immune Response 52

The Pharma Data

SEPTEMBER 1, 2021

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced today the initiation of the Phase 3 MOVe-AHEAD clinical trial to evaluate molnupiravir, an investigational oral antiviral therapeutic, for the prevention of COVID-19 infection. MOVe-AHEAD Study.

Laboratories 52

Laboratories Virus Clinical Trials Research Laboratories 52